Valbiotis (ALVAL.PA) Stock Price

Valbiotis Price

Euronext·CLOSED
0.77EUR-0.0030 (-0.39 %)
Market closed

Over the last 7 years Valbiotis grew revenue by 78.8% annually, reaching 175,000.00 EUR. For Valbiotis, the net margin of -5,728.6% is down versus -123.8% a few years ago. The consensus 12-month price target for Valbiotis is 2.14 EUR, about 178.2% above where the stock trades today. Of 11 analysts, 10 rate the stock a buy — an overall Buy consensus. The stock trades about 40% above its 52-week low.

Valbiotis stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Valbiotis over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Valbiotis stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Valbiotis's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Valbiotis Stock Price History
DateValbiotis Price
7/31/20260.77 EUR
7/30/20260.77 EUR
7/29/20260.76 EUR
7/28/20260.76 EUR
7/27/20260.78 EUR
7/24/20260.79 EUR
7/23/20260.79 EUR
7/22/20260.79 EUR
7/21/20260.77 EUR
7/20/20260.77 EUR
7/17/20260.78 EUR
7/16/20260.79 EUR
7/15/20260.78 EUR
7/14/20260.79 EUR
7/13/20260.80 EUR
7/10/20260.79 EUR
7/9/20260.78 EUR
7/8/20260.81 EUR
7/7/20260.80 EUR
7/6/20260.82 EUR
7/3/20260.86 EUR
7/2/20260.83 EUR
7/1/20260.79 EUR
6/30/20260.80 EUR
6/29/20260.80 EUR
6/26/20260.75 EUR
6/25/20260.80 EUR
6/24/20260.85 EUR
6/23/20260.87 EUR
6/22/20260.86 EUR
6/19/20260.86 EUR
6/18/20260.89 EUR
6/17/20260.89 EUR
6/16/20260.88 EUR
6/15/20260.88 EUR
6/12/20260.89 EUR
6/11/20260.89 EUR
6/10/20260.89 EUR
6/9/20260.89 EUR
6/8/20260.91 EUR
6/5/20260.98 EUR
6/4/20261.04 EUR
6/3/20261.10 EUR
6/2/20261.08 EUR
6/1/20261.14 EUR
5/29/20261.15 EUR
5/28/20261.18 EUR
5/27/20261.07 EUR
5/26/20261.08 EUR
5/25/20261.11 EUR
5/22/20261.05 EUR
5/21/20261.02 EUR
5/20/20261.05 EUR
5/19/20261.08 EUR
5/18/20261.09 EUR
5/15/20261.10 EUR
5/14/20261.22 EUR
5/13/20261.19 EUR
5/12/20261.04 EUR
5/11/20260.93 EUR
5/8/20260.94 EUR
5/7/20260.95 EUR
5/6/20260.94 EUR
5/5/20260.92 EUR
5/4/20260.93 EUR
4/30/20260.93 EUR
4/29/20260.93 EUR
4/28/20260.97 EUR
4/27/20260.97 EUR
4/24/20261.01 EUR
4/23/20261.00 EUR
4/22/20261.01 EUR
4/21/20261.01 EUR
4/20/20261.01 EUR
4/17/20261.02 EUR
4/16/20261.09 EUR
4/15/20261.08 EUR
4/14/20261.07 EUR
4/13/20261.06 EUR
4/10/20261.03 EUR
4/9/20260.99 EUR
4/8/20261.02 EUR
4/7/20260.99 EUR
4/2/20261.07 EUR
4/1/20261.09 EUR
3/31/20261.05 EUR
3/30/20260.98 EUR
3/27/20261.01 EUR
3/26/20261.03 EUR
3/25/20261.03 EUR
3/24/20261.03 EUR
3/23/20261.07 EUR
3/20/20261.07 EUR
3/19/20260.96 EUR
3/18/20261.01 EUR
3/17/20260.99 EUR
3/16/20261.01 EUR
3/13/20261.00 EUR
3/12/20261.01 EUR
3/11/20261.05 EUR
3/10/20261.05 EUR
3/9/20260.99 EUR
3/6/20261.03 EUR
3/5/20261.06 EUR
3/4/20261.02 EUR
3/3/20260.96 EUR
3/2/20260.98 EUR
2/27/20261.03 EUR
2/26/20261.01 EUR
2/25/20260.97 EUR
2/24/20261.01 EUR
2/23/20261.00 EUR
2/20/20261.03 EUR
2/19/20261.03 EUR
2/18/20261.04 EUR
2/17/20261.06 EUR
2/16/20261.04 EUR
2/13/20261.06 EUR
2/12/20261.09 EUR
2/11/20261.09 EUR
2/10/20261.10 EUR
2/9/20261.12 EUR
2/6/20261.09 EUR
2/5/20261.13 EUR
2/4/20261.21 EUR
2/3/20261.18 EUR
2/2/20261.00 EUR
1/30/20261.05 EUR
1/29/20260.95 EUR
1/28/20261.10 EUR
1/27/20260.82 EUR
1/26/20260.71 EUR
1/23/20260.72 EUR
1/22/20260.70 EUR
1/21/20260.70 EUR
1/20/20260.69 EUR
1/19/20260.69 EUR
1/16/20260.70 EUR
1/15/20260.70 EUR
1/14/20260.70 EUR
1/13/20260.73 EUR
1/12/20260.74 EUR
1/9/20260.71 EUR
1/8/20260.69 EUR
1/7/20260.69 EUR
1/6/20260.69 EUR
1/5/20260.68 EUR
1/2/20260.72 EUR
12/31/20250.69 EUR
12/30/20250.70 EUR
12/29/20250.68 EUR
12/24/20250.70 EUR
12/23/20250.67 EUR
12/22/20250.66 EUR
12/19/20250.65 EUR
12/18/20250.65 EUR
12/17/20250.63 EUR
12/16/20250.64 EUR
12/15/20250.68 EUR
12/12/20250.69 EUR
12/11/20250.70 EUR
12/10/20250.69 EUR
12/9/20250.71 EUR
12/8/20250.68 EUR
12/5/20250.71 EUR
12/4/20250.71 EUR
12/3/20250.70 EUR
12/2/20250.71 EUR
12/1/20250.71 EUR
11/28/20250.71 EUR
11/27/20250.73 EUR
11/26/20250.70 EUR
11/25/20250.74 EUR
11/24/20250.71 EUR
11/21/20250.71 EUR
11/20/20250.82 EUR
11/19/20250.83 EUR
11/18/20250.91 EUR
11/17/20250.58 EUR
11/14/20250.55 EUR
11/13/20250.56 EUR
11/12/20250.59 EUR
11/11/20250.60 EUR
11/10/20250.58 EUR
11/7/20250.60 EUR
11/6/20250.60 EUR
11/5/20250.58 EUR
11/4/20250.61 EUR
11/3/20250.64 EUR
10/31/20250.67 EUR
10/30/20250.73 EUR
10/29/20250.74 EUR
10/28/20250.76 EUR
10/27/20250.75 EUR
10/24/20250.73 EUR
10/23/20250.74 EUR
10/22/20250.74 EUR
10/21/20250.77 EUR
10/20/20250.74 EUR
10/17/20250.78 EUR
10/16/20250.79 EUR
10/15/20250.76 EUR
10/14/20250.74 EUR
10/13/20250.79 EUR
10/10/20250.81 EUR
10/9/20250.80 EUR
10/8/20250.81 EUR
10/7/20250.79 EUR
10/6/20250.82 EUR
10/3/20250.81 EUR
10/2/20250.81 EUR
10/1/20250.82 EUR
9/30/20250.79 EUR
9/29/20250.78 EUR
9/26/20250.79 EUR
9/25/20250.81 EUR
9/24/20250.80 EUR
9/23/20250.81 EUR
9/22/20250.80 EUR
9/19/20250.79 EUR
9/18/20250.80 EUR
9/17/20250.84 EUR
9/16/20250.86 EUR
9/15/20250.83 EUR
9/12/20250.82 EUR
9/11/20250.81 EUR
9/10/20250.81 EUR
9/9/20250.81 EUR
9/8/20250.81 EUR
9/5/20250.80 EUR
9/4/20250.80 EUR
9/3/20250.83 EUR
9/2/20250.83 EUR
9/1/20250.86 EUR
8/29/20250.86 EUR
8/28/20250.86 EUR
8/27/20250.85 EUR
8/26/20250.85 EUR
8/25/20250.86 EUR
8/22/20250.88 EUR
8/21/20250.88 EUR
8/20/20250.90 EUR
8/19/20250.90 EUR
8/18/20250.91 EUR
8/15/20250.90 EUR
8/14/20250.89 EUR
8/13/20250.89 EUR
8/12/20250.88 EUR
8/11/20250.83 EUR
8/8/20250.83 EUR
8/7/20250.83 EUR
8/6/20250.80 EUR
Access this data via the Eulerpool API
Get Free API Key

Valbiotis Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
3.09 M EUR
-3.41 M EUR
-3.83 M EUR
Jan 1, 2021
298,000.00 EUR
-8.48 M EUR
-8.68 M EUR
Jan 1, 2022
785,000.00 EUR
-12.03 M EUR
-12.31 M EUR
Jan 1, 2023
4.73 M EUR
-7.18 M EUR
-7.37 M EUR
Jan 1, 2024
175,000.00 EUR
-10.42 M EUR
-10.03 M EUR
Jan 1, 2025 (e)
927,000.00 EUR
-9.42 M EUR
-11.31 M EUR
Jan 1, 2026 (e)
5.00 M EUR
-6.08 M EUR
-7.16 M EUR
Jan 1, 2027 (e)
15.86 M EUR
-618,000.00 EUR
-610,275.03 EUR

Valbiotis Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 5, 2026, 8:46 PM
 
REVENUEM EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM EUR
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
SHARESM
2016201720182019202020212022202320242025e2026e2027e
––––3.00––4.00––4.0015.00
–––––––––––275.00
––––66.67––50.00––-75.00-20.00
-3.00-3.00-3.00-3.002.00-3.00-3.002.00-3.00-3.00-3.00-3.00
–-2.00-4.00-5.00-3.00-8.00-12.00-7.00-10.00-9.00-6.00–
––––-100.00––-175.00––-150.00–
–-2.00-4.00-5.00-3.00-8.00-12.00-7.00-10.00-11.00-7.00–
––100.0025.00-40.00166.6750.00-41.6742.8610.00-36.36–
2.303.673.804.707.459.1610.1812.5415.8915.8915.8915.89
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Valbiotis generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Valbiotis retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Valbiotis's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Valbiotis has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Valbiotis's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Valbiotis stock margins

The Valbiotis margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Valbiotis. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Valbiotis.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
81.63 %
-110.19 %
-123.84 %
Jan 1, 2021
-39.93 %
-2,843.96 %
-2,913.09 %
Jan 1, 2022
28.54 %
-1,531.97 %
-1,568.41 %
Jan 1, 2023
48.76 %
-151.70 %
-155.67 %
Jan 1, 2024
-1,796.57 %
-5,956.00 %
-5,728.57 %
Jan 1, 2025 (e)
-1,796.57 %
-1,016.67 %
-1,220.10 %
Jan 1, 2026 (e)
-1,796.57 %
-121.64 %
-143.32 %
Jan 1, 2027 (e)
-1,796.57 %
-3.90 %
-3.85 %

Valbiotis Stock Revenue, EBIT, Earnings per Share

The Valbiotis earnings per share therefore indicates how much revenue Valbiotis has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
0.41 EUR
-0.46 EUR
-0.51 EUR
Jan 1, 2021
0.03 EUR
-0.93 EUR
-0.95 EUR
Jan 1, 2022
0.08 EUR
-1.18 EUR
-1.21 EUR
Jan 1, 2023
0.38 EUR
-0.57 EUR
-0.59 EUR
Jan 1, 2024
0.01 EUR
-0.66 EUR
-0.63 EUR
Jan 1, 2025 (e)
0.04 EUR
-0.59 EUR
-0.48 EUR
Jan 1, 2026 (e)
0.21 EUR
-0.38 EUR
-0.30 EUR
Jan 1, 2027 (e)
0.67 EUR
-0.04 EUR
-0.03 EUR

Valbiotis business model & stock analysis

Valbiotis SA is a French company specializing in the research and development of new and innovative treatment options based on plant-derived ingredients. The company was founded in 2014 by Sebastien Peltier, an experienced employee in the pharmaceutical industry, who wanted to search for new and effective therapeutic possibilities. Valbiotis' business model is based on identifying and utilizing new plant-derived ingredients to develop therapies that cater to market needs. The company works closely with various partners, universities, and research organizations to ensure that their products are based on the latest scientific findings. One of Valbiotis' main areas of focus is the development of products to support metabolism and metabolic health. They utilize solutions based on a plant-derived ingredient called TOTUM-63, which aims to treat and prevent risk factors such as obesity, insulin resistance, and metabolic diseases like Type 2 diabetes. Valbiotis has also established a comprehensive research department to explore further applications for their plant-derived ingredients, including cardiovascular diseases and neurodegenerative diseases like Alzheimer's. One of Valbiotis' most well-known products is TOTUM-63, a plant-derived ingredient that has positive effects on metabolism. TOTUM-63 consists of four different plant-derived ingredients and is intended to restore balance to metabolism and support the body in combating risk factors such as obesity and Type 2 diabetes. The company is currently seeking further promising applications for TOTUM-63. Valbiotis has also formed partnerships with major pharmaceutical companies such as Nestlé Health Science and Nestlé Research to fund their research and optimize the use of their plant-derived ingredients. Additionally, Valbiotis collaborates with various universities and research institutions to incorporate the latest scientific findings into their products. Overall, Valbiotis is one of the most promising companies in the pharmaceutical industry focused on plant-derived ingredients. The company has developed a wide range of products and applications and works closely with various partners to develop innovative therapy options based on plant-derived ingredients. Valbiotis is well-positioned to achieve further growth in the future and treat and prevent diseases in a new way.

Valbiotis SWOT Analysis

Strengths

Valbiotis SA has a strong product portfolio consisting of innovative health solutions.

The company has a dedicated and experienced team with strong expertise in the field of biotechnology.

Valbiotis SA has established partnerships with reputable companies, ensuring access to distribution channels and potential collaborations.

Weaknesses

Valbiotis SA operates in a highly competitive market, which poses challenges in terms of market share and pricing.

The company relies heavily on the success of its research and development efforts, making it susceptible to uncertainties.

Valbiotis SA may face financial constraints in scaling up production or expanding its product line.

Opportunities

The growing demand for natural and preventive healthcare products presents a significant opportunity for Valbiotis SA to expand its customer base.

Valbiotis SA can leverage emerging markets and global trends towards holistic health and wellness.

The increasing interest in personalized nutrition provides an avenue for Valbiotis SA to develop tailored products and services.

Threats

Valbiotis SA is subject to strict regulations and compliance requirements in the healthcare industry, which could impact its operations.

The presence of substitute products and alternative therapies may pose a threat to Valbiotis SA's market position.

Economic downturns or market fluctuations can impact consumer spending habits, potentially affecting the demand for Valbiotis SA's products.

Valbiotis Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Valbiotis historical P/E ratio, EBIT multiple, and P/S ratio

Valbiotis annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Valbiotis shares outstanding

The number of shares of Valbiotis was 15.89 M in 2025. This indicates how many shares Valbiotis is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
7.45 M Stocks
Jan 1, 2021
9.16 M Stocks
Jan 1, 2022
10.18 M Stocks
Jan 1, 2023
12.54 M Stocks
Jan 1, 2024
15.89 M Stocks
Jan 1, 2025 (e)
15.89 M Stocks
Jan 1, 2026 (e)
15.89 M Stocks
Jan 1, 2027 (e)
15.89 M Stocks

Current Valbiotis forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
90.91 % (10)
Hold
9.09 % (1)
Sell
0.00 % (0)
12M Price Target
2.14
Last Price
0.77
Currency
EUR
12M Return Potential
179.27 %
LTM Return
0 %

Valbiotis shareholder structure

% Name
2.73388%
Peltier (Sebastien)
Peltier (Sebastien)
0.71759%
Talence Gestion, SAS
Talence Gestion, SAS
0.67022%
Pure Capital S.A.
Pure Capital S.A.
0.50633%
OFI Invest Asset Management
OFI Invest Asset Management
0.14307%
Sirvent (Pascal)
Sirvent (Pascal)
0.07049%
Cazaubiel (Murielle Anne)
Cazaubiel (Murielle Anne)

Valbiotis Executives and Management Board

8 members · avg. age 53 · 25 % women

SP

Dr. Sebastien Peltier

Chief Executive Officer, Co-Founder, Member of the Executive Committee

259,500.00 EUR

Management

MC

Ms. Murielle Cazaubiel

CMO, Head - Medical, Regulatory and Industrial Affairs, Member of the Executive Committee · since 2024

206,700.00 EUR
PS

Mr. Pascal Sirvent

Chief Scientific Officer, Member of the Executive Board · since 2023

193,600.00 EUR
SB

Mr. Sebastien Bessy

Chief Operating Officer, Head - Marketing and Commercial Operations, Member of the Executive Committee

104,000.00 EUR
SS

Mr. Stanislas Sordet

Chief Financial Officer, Head - Administration and Finance, Member of the Executive Committee

–

Board of Directors

AT

Ms. Agnes Tixier

Independent Member of the Supervisory Board

99,900.00 EUR
JZ

Mr. Jean Zetlaoui

Independent Member of the Supervisory Board

99,900.00 EUR
LL

Dr. Laurent Levy (53)

Independent Chairman of the Supervisory Board · since 2017

–

Frequently asked questions about Valbiotis

Valbiotis SA is a biotechnology company focused on developing innovative solutions for preventing and managing metabolic diseases. Their business model revolves around the research, development, and commercialization of health solutions based on natural plant extracts. Valbiotis SA aims to address unmet medical needs through scientific expertise, strong partnerships, and an extensive portfolio of patented products. By leveraging their deep knowledge of metabolic disorders and targeting key markets, Valbiotis SA strives to provide effective and safe therapies to improve health outcomes for individuals suffering from metabolic diseases.

Valbiotis SA is primarily active in the pharmaceutical and biotechnology industries.

The main competitors of Valbiotis SA in the market include companies such as Amarin Corporation, Provention Bio Inc., and Sanofi SA.

Valbiotis SA is a French company specializing in the scientific research and development of innovative solutions for preventing and combating metabolic diseases. Founded in 2014, Valbiotis focuses on the discovery of therapeutic products derived from natural plant-based substances. Their aim is to address prevalent health issues such as obesity, type 2 diabetes, and cardiovascular diseases. With a dedicated team of experts and a rigorous approach to clinical trials, Valbiotis is committed to revolutionizing healthcare by offering safe, effective, and accessible solutions. Through continuous innovation and strategic partnerships, Valbiotis SA is poised to make a significant impact in the field of metabolic disorders.

Valbiotis SA has achieved several significant milestones throughout its journey. One noteworthy accomplishment for Valbiotis SA is the development and launch of its flagship product TOTUM-63. This innovative product targets metabolic diseases and has shown promising results in clinical trials. Additionally, Valbiotis SA has successfully formed strategic partnerships with renowned pharmaceutical companies, enhancing its reach and potential for future growth. Another achievement for the company is its listing on the Euronext Growth Paris stock exchange, which further solidifies its presence in the market. Valbiotis SA's continuous dedication to research, development, and market expansion shapes a promising future for the company.

Valbiotis SA is primarily present in France.

Valbiotis SA represents the values of innovation, scientific rigor, and sustainability. The company is dedicated to developing scientifically validated solutions for preventing and managing metabolic diseases. Valbiotis SA's corporate philosophy promotes a patient-centric approach, aiming to improve their quality of life and provide them with effective and safe health solutions. With a focus on research and collaboration, Valbiotis SA aims to tackle major global health challenges and contribute to the well-being of individuals affected by metabolic disorders. Through its commitment to excellence and ethical practices, Valbiotis SA strives to make a positive impact on the healthcare industry.

Analysts currently set an average price target of 2.18 EUR for the Valbiotis stock (median: 2.14 EUR), implying +183.7 % versus the latest price. The consensus is based on 11 analyst ratings.

Valbiotis Analyst Price Targets 2026

11 analysts currently rate the Valbiotis stock: 10 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Valbiotis to generate revenue of 5.00 M EUR and earnings per share of -0.45 EUR.

Valbiotis Analyst Price Targets 2026

The Valbiotis share (ALVAL.PA) is listed on 4 stock exchanges, including: Frankfurt (8JD.F), München (8JD.MU), Paris (ALVAL.PA).

Valbiotis SA is a French biotech company specializing in the development of innovative solutions for treating metabolic diseases. The business model is based on selling patented products and collaborating with leading companies in the food and pharmaceutical industries. The company focuses on developing drugs and products for treating diabetes, obesity, cholesterol, triglycerides, and non-alcoholic steatohepatitis (NASH). Valbiotis works closely with the food industry to develop dietary solutions. The company has received awards and has partnerships with European universities and research institutions. Overall, Valbiotis SA aims to improve the health and well-being of patients with metabolic diseases through innovation and is a pioneer in a new era of treatment methods.

The expected revenue of Valbiotis is 5.00 M EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Valbiotis is -7.16 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Valbiotis is currently -1.71. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Valbiotis stock.

The price-to-sales ratio (P/S) of Valbiotis is currently 2.45. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Valbiotis stock.

The Eulerpool Quality Score for Valbiotis is 2/10.

The ISIN of Valbiotis is FR0013254851. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Valbiotis is A2DS5F. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Valbiotis is ALVAL.PA. The ticker symbol is used to trade Valbiotis shares on the stock exchange.

Valbiotis paid dividends every year for the past 0 years.

Valbiotis is assigned to the 'Health' sector.

The dividends of Valbiotis are distributed in EUR.

All fundamentals and in-depth analysis of Valbiotis

Our stock analysis for Valbiotis stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Valbiotis. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Valbiotis Stock
Valbiotis Revenue→
Valbiotis Stock
Valbiotis Net Income→
Valbiotis Stock
Valbiotis P/E→
Valbiotis Stock
Valbiotis P/S→
Valbiotis Stock
Valbiotis EBIT→
Valbiotis Stock
Valbiotis Dividend→
Valbiotis Stock
Valbiotis Directors Dealings→
Valbiotis Stock
Valbiotis Stocks→
Valbiotis Stock
Valbiotis Market capitalization→
Valbiotis Stock
Valbiotis Debt→
Valbiotis Stock
Valbiotis Liabilities→
Valbiotis Stock
Valbiotis Equity→
Valbiotis Stock
Valbiotis AAQS→
Valbiotis Stock
Valbiotis Employees→
Valbiotis Stock
Valbiotis ROE→
Valbiotis Stock
Valbiotis ROA→
Valbiotis Stock
Valbiotis ROCE→
Valbiotis Stock
Valbiotis News→
Valbiotis Stock
Valbiotis Analyst Price Targets→

Health Stocks

Valerio TherapeuticsVaishali PharmaValiant LaboratoriesVaidya Sane Ayurved LaboratoriesValiRxVaccinexValnevaUtah Medical ProductsValneva SE ADRUscomValue Added Technology CoUS Stem CellAll Stocks A–Z →